Transgene SA
Research Transgene SA (0OCQ) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0OCQ
- ExchangeLSE
- CountryFrance
- SectorCommunication Services
- IndustryBroadcasting
- CurrencyEUR
- Financial periodFY2025
- RevenueEUR 137.00K
- Revenue growth291.4%
- Net income-EUR 37.52M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 137.00K | -EUR 37.52M | n/a | n/a | -0.26 | EUR 6.66M | EUR 1.66M | EUR 121.74M |
| FY2024 | EUR 35.00K | -EUR 33.97M | n/a | n/a | -0.29 | EUR 16.67M | EUR 10.22M | EUR 15.20M |
| FY2023 | EUR 1.18M | -EUR 22.33M | n/a | n/a | -0.22 | EUR 15.67M | EUR 15.96M | EUR 15.61M |
| FY2022 | EUR 3.13M | -EUR 32.80M | n/a | n/a | -0.33 | EUR 4.40M | EUR 12.33M | EUR 37.84M |
| FY2021 | EUR 9.99M | -EUR 19.54M | n/a | n/a | -0.21 | EUR 5.91M | EUR 15.24M | EUR 67.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-19 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.52 EUR |
| FY2024 | 0.5 EUR |
| FY2023 | 0.42 EUR |
| FY2022 | 0.4 EUR |
| FY2021 | 0.37 EUR |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
Related stock research
Other Communication Services stocks
Frequently asked questions
What does Transgene SA do?
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.